Q1 FY2027 · ended Jun 30, 2026 · Revenue $4.28M, +10.4% YoY · Filed Aug 19, 2026
Biotricity Inc. (BTCY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q1 of fiscal 2027, the quarter ended Jun 30, 2026, it reported revenue of $4.3 million and a net loss of $959,468. As of Jun 30, 2026 it held $466,503 in cash and investments and $252,172 in total debt.
Revenue
$4.28M
+10.4% vs year-ago quarter
Net income
$-959,468
-42.8% vs year-ago quarter
Operating cash flow
$507,227
+235.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.05
-58.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
19.91M
-25.0% vs year-ago quarter
Net cash
$214,331
Q1 FY2027
Operating margin
9.6%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BTCY (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1630113
- Former names
- METASOLUTIONS, INC. (until Jan 5, 2016)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $4.3M | $4.3M | $4.0M | $3.9M | $3.9M |
| Operating income | $158,068 | $694,557 | $440,915 | $273,819 | $281,945 |
| Net income | -$959,468 | -$324,182 | -$717,067 | -$690,913 | -$671,977 |
| Diluted EPS | -$0.05 | -$0.02 | -$0.04 | -$0.03 | -$0.03 |
| Operating cash flow | $507,227 | -$20,905 | -$740,291 | $415,630 | -$373,389 |
| Total assets | $6.0M | $6.4M | $5.7M | $6.3M | $6.0M |
| Total liabilities | $39.7M | $39.4M | $38.2M | $38.0M | $36.8M |
| Stockholders' equity | -$35.4M | -$34.7M | -$34.2M | -$33.4M | -$32.8M |
| Cash and investments | $466,503 | $149,789 | $256,357 | $308,460 | $391,292 |
| Total debt | $252,172 | $397,830 | $539,398 | $674,013 | $803,380 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 28, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-K | Annual report | Jul 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
May 1, 2026 | May 1, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 18, 2026 | Feb 11, 2026 |
| 10-Q | Quarterly report | Feb 11, 2026 | Dec 31, 2025 |
All 317 Biotricity Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.